Allergy medication recalled nationwide over contamination concerns

Unique Pharmaceutical Laboratories has initiated a voluntary nationwide recall of four specific lots of Cetirizine Hydrochloride Tablets USP 5 mg. The decision follows a report from a pharmacy technician who identified red dots and discoloration on the tablets. Investigators determined these markings suggest cross-contamination with ranitidine, a drug previously used to treat stomach acid issues.

The recalled products are packaged in 100-count HDPE bottles and distributed by Rising Pharma Holdings Inc. The National Drug Code for these items is 16571-401-10. Consumers should check their bottles for the following lot numbers: GY825029, GY825030, GY825031, and GY825032. All listed lots have an expiration date of October 2028.

While the manufacturer reports no adverse events linked to this issue, individuals with sensitivities to ranitidine face risks if they consume the contaminated medication. Exposure may trigger severe hypersensitivity reactions, including difficulty breathing, throat swelling, and anaphylaxis. Anyone experiencing negative symptoms after using this product should seek medical attention.

Rising Pharma Holdings Inc. is currently coordinating the return of the affected stock from wholesalers and retailers. Customers with questions regarding the recall process can contact the company via phone at 1-844-874-7464 or email their quality assurance team. Reports regarding potential adverse reactions can also be submitted to the FDA through the MedWatch program.